40th week of 2014 patent applcation highlights part 49 |
Patent application number | Title | Published |
20140294728 | Systems and methods for detecting efforts to thwart material detection by service animals - Methods and systems for detecting efforts to thwart the sense of smell of service animals and sniffer dogs. Methods and systems for detecting the introduction of and for neutralizing the effects of ONM introduced into an area. Methods and systems for the controlling the direction of the emission or ONM or descanter into an area. This abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure and is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims, 37 C.F.R. 1.72(b). | 2014-10-02 |
20140294729 | METHODS FOR IDENTIFICATION AND USE OF AGENTS TARGETING CANCER STEM CELLS - The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof. | 2014-10-02 |
20140294730 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND MONITORING OVARIAN CANCER PROGRESSION AND TREATMENT - The present invention provides compositions and methods useful for diagnosing, monitoring the progression, identifying the location, and monitoring the treatment response in ovarian cancer based on detecting and locating VCAM-1 expression. | 2014-10-02 |
20140294731 | PHOSPHOSPECIFIC ANTIBODIES RECOGNISING TAU - The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD). | 2014-10-02 |
20140294732 | Early diagnostic of neurodegenerative diseases - The present application provides a method for diagnosing a neurodegenerative disease in a subject at risk of having said neurodegenerative disease, said method comprising the steps of a) having said subject at risk of having said neurodegenerative disease perform a series of fast, brief and powerful movements that recruit fast-fatigable motoneurons (ballistic movements), and b) comparing the performance in step a) of said subject at risk of having said neurodegenerative disease with a standard value obtained by assessing the performance of a normal population for the same series of fast, brief and powerful movements that recruit fast-fatigable motoneurons, wherein a significant deviation of performance by said subject at risk of having said neurodegenerative disease is indicative of the onset of said neurodegenerative disease. | 2014-10-02 |
20140294733 | MULTIFUNCTIONAL SMALL MOLECULES - The present invention relates to dendrimer synthesis. Specifically, the present invention relates to dendrimer compositions (e.g., scaffolds) capable of copper-free click conjugation for use in the synthesis of functionalized dendrimers, and methods of use of the same. | 2014-10-02 |
20140294734 | Magnetic Resonance Imaging (MRI) Based Quantitative Kidney Perfusion Analysis - Example apparatus and methods provide improved spatial and temporal resolution over conventional magnetic resonance renography (MRR). Example apparatus and methods reconstruct under-sampled three-dimensional (3D) data associated with nuclear magnetic resonance (NMR) signals acquired from a kidney. The data is reconstructed using a 3D through-time non-Cartesian generalized auto-calibrating partially parallel acquisitions (GRAPPA) approach. Example apparatus and methods produce a quantized value for a contrast agent concentration in the kidney from a signal intensity in the data based, at least in part, on a two compartment model of the kidney. The two compartment model includes a plasma compartment and a tubular compartment. The quantized value describes a perfusion parameter for the kidney or a filtration parameter for the kidney. Greater precision is achieved for estimates of the perfusion parameter or filtration parameter as a result of the quantization performed on data acquired with greater spatial resolution and temporal resolution. | 2014-10-02 |
20140294735 | POLYMER-TYPE FLUORESCENT MOLECULE PROBE - The present invention provides a fluorescent molecular probe for efficient fluorescent detection (visualization) of tumors or for implementing fluorescent detection and photodynamic treatment, more specifically, the present invention provides a macromolecular fluorescent molecular probe for fluorescent detection of tumor, comprising a complex comprising a fluorescent molecule and a biocompatibie macromolecule. | 2014-10-02 |
20140294736 | TOOTHPASTE - A dental brushing composition including a brushing composition base additionally containing a plurality of microparticles, the particles comprising a core, a coating essentially completely surrounding the core, and two different flavors, a general flavor and an indicator flavor, the general flavor being in the coating and the indicator flavor in the core, the coating being essentially completely soluble under brushing conditions in a desired brushing time. The composition signals when a desired brushing time has been achieved by a noticeable change in flavor. | 2014-10-02 |
20140294737 | TREATMENT OF RHINITIS - The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a danazol compound or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical product formulated for nasal administration. The product comprises a danazol compound or a pharmaceutically acceptable salt thereof. | 2014-10-02 |
20140294738 | TREATMENT OF RHINITIS - The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition. | 2014-10-02 |
20140294739 | COMPOSITIONS CONTAINING ZINC SALTS AND ISOTHIOCYANATES FOR REDUCTION OF ORAL VOLATILE SULFUR COMPOUNDS (VSCs) - Combinations of a zinc salt and an isothiocyanate are provided, and more particularly to a consumer acceptable oral composition containing such combination which is effective in the reduction of volatile sulfur compounds (VSCs). | 2014-10-02 |
20140294740 | ORAL CARE COMPOSITIONS - Described herein are compositions comprising a low abrasive silica and a fine silica thickener, and suspended elements, along with methods for making and using the same. | 2014-10-02 |
20140294741 | Enamel protectant and Repair Toothpaste Treatments - Substantially aqueous-free, enamel protectant and enamel repair toothpaste treatments containing: stannous fluoride, calcium and a substantivity agent comprising: an emulsion of polydimethylsiloxane in a nonionic surfactant, wherein: (a) substantivity of said stannous fluoride and calcium into biofilm present on enamel is enhanced through calcium binding shifting from bidentate to monodentate in the presence of stannous fluoride; and (b) said toothpaste treatments indicate substantially improved, enamel protectant factor (EPF) and enamel repair factor (ERF) values compared to fluoride brushing treatments with comparable or higher fluoride levels. | 2014-10-02 |
20140294742 | ANTI-PLAQUE DENTAL COMPOSITIONS - Anti-plaque dental treatment compositions are useful in treating and/or preventing formation of dental plaque and biofilm. The anti-plaque compositions are configured for daily application to a patient's teeth in order to inhibit dental plaque formation and generally include a peroxide-based anti-bacterial compound, xylitol in an amount so as to provide a bacteriostatic effect, and an aqueous gel carrier comprised of water and at least one thickening agent into which the anti-bacterial compound and xylitol are dispersed. | 2014-10-02 |
20140294743 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES - The present invention relates to a cosmetic and/or dermatological composition comprising in a physiologically acceptable medium at least one merocyanine derivative of formula (1) or (2) and/or its E,E-, E,Z- or Z,Z-geometrical isomer forms: comprising specific polar groups consisting of hydroxyl- and ether-functionalities. Another object of the present invention relates to a cosmetic process for controlling and/or improving the darkening of the skin under exposure to UV radiation and the homogeneity of the colour of the complexion which comprises the application onto the skin of a cosmetic composition as above defined. Another object of the present invention relates to a cosmetic process for protecting the keratinic materials and particularly the skin against photo-ageing which comprises the application onto the keratinic material of a cosmetic composition as above defined. | 2014-10-02 |
20140294744 | ALKYL KETAL ESTERS AS DISPERSANTS AND SLIP AGENTS FOR PARTICULATE SOLIDS, METHODS OF MANUFACTURE, AND USES THEREOF - Disclosed herein is a dispersion comprising a liquid or semi-solid continuous phase, a dispersed solid phase comprising a plurality of organic, inorganic or inorganic-organic particles, and an alkyl ketal ester having the structure | 2014-10-02 |
20140294745 | CORAL EXTRACT FOR SKIN WHITENING, MOISTURE RETENTION, ELASTICITY IMPROVEMENT, ANTI-INFLAMMATION AND OCCLUSION OF WOUNDS AND EXTRACTING METHOD THEREOF - A coral extract for skin whitening, moisture retention, elasticity improvement, anti-inflammation and occlusion of wounds and its extracting method is provided. The coral extract is extracted from | 2014-10-02 |
20140294746 | Aminofunctional Silicone Emulsions - Aqueous silicone emulsions are disclosed comprising: A) an aminofunctional organopolysiloxane, B) a quaternary ammonium surfactant having a formula R | 2014-10-02 |
20140294747 | HAIR THERAPY PRODUCT CONTAINING NO ARYLATED SILICONES - A hair treatment medium having the absence of arylated silicones includes a) at least one diester of the propylene glycol according to the formula (I), in which R and R denote, independently of one another, a residue selected from at least one linear, saturated or unsaturated, branched, saturated or unsaturated and cyclical saturated or unsaturated C6 to C30 hydrocarbon residue and/or a phenyl or benzyl residue substituted with C1 to C4 alkyl groups and/or hydroxy groups, and the compounds thereof in an overall volume of 0.01 to 5.0% by weight, and b) at least one protein hydrolysate and compounds of protein hydrolysates in an overall volume of 0.01 to 10.0% by weight, and c) at least one C1-C6 alcohol in an overall volume of 1.0% by weight to 40.0% by weight in the absence of arylated silicone oils. | 2014-10-02 |
20140294748 | HAIR TREATMENT WITHOUT ARYLATED SILICONES - A hair treatment medium including diesters of propylene glycol and protein hydrolysates in the absence of arylated silicones includes at least one diester of the propylene glycol according to the formula (I), in which R1 and R2 denote, independently of one another, a residue selected from at least one linear, saturated or unsaturated, branched, saturated or unsaturated and cyclical saturated or unsaturated C6 to C30 hydrocarbon residue and/or a phenyl or benzyl residue substituted with C1 to C4 alkyl groups and/or hydroxy groups, and the compounds thereof in an overall volume of 0.01 to 5.0% by weight, at least one protein hydrolysate and compounds of protein hydrolysates in an overall volume of 0.01 to 10.0% by weight, and at least one C1-C6 alcohol in an overall volume of 1.0% by weight to 40.0% by weight. | 2014-10-02 |
20140294749 | WATER SOLUBLE ANTIMICROBIAL COMPOSITION - The present invention provides for antimicrobial compositions, methods of preparing the antimicrobial compositions, methods of using the antimicrobial compositions, and/or kits that include the antimicrobial compositions. The antimicrobial compositions can be in a dry, solid (e.g., powdered) form, or can be in a liquid (e.g., aqueous) form. | 2014-10-02 |
20140294750 | AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING BORATE-POLYOL COMPLEXES - The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate, a preservative or both. | 2014-10-02 |
20140294751 | Hemocompatibility Modifiers for Cross-Linked Polymeric Material - The invention concerns methods of treating blood, blood product, or physiologic fluid to provide at least one of (i) increasing shelf life of the blood, blood product or physiologic fluid, (ii) maintaining freshness of new blood, blood product or physiologic fluid, and (iii) removing undesirable molecules from the blood, blood product or physiologic fluid; said method comprising contacting said blood, blood product or physiologic fluid with a sorbent, said sorbent being primarily in a plurality of solid forms and comprising a cross-linked polymeric material having a plurality of at least one of (1) zwitterionic moieties and (2) oligo(ethylene glycol) moieties attached to the surface of said cross-linked polymeric material. | 2014-10-02 |
20140294752 | METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID - A hyaluronic acid conjugates including hyaluronic acid, a disulfide bond-containing crosslinking agent, and a cationic, amphiphilic polymer; a hyaluronic acid-nucleic acid complex in which a nucleic acid is bound to the hyaluronic acid conjugate; a composition in which the hyaluronic acid-nucleic acid complexes are crosslinked with each other; a nucleic acid delivery composition including the hyaluronic acid-nucleic acid complex; and a method of nucleic acid delivery using the hyaluronic acid-nucleic acid complex. | 2014-10-02 |
20140294753 | NOVEL USE OF GANODERMIC ACIDS FOR TREATING CANCER - Novel Uses of a small molecule, ganodermic acid S (GMAS), are disclosed herein. The GMAS is useful as a lead compound for manufacturing a medicament or a pharmaceutical composition for treating cancer, including metastatic or drug-resistant cancer, in a patient. | 2014-10-02 |
20140294754 | USE OF TUMOR FAS EXPRESSION TO DETERMINE RESPONSE TO ANTI-CANCER THERAPY - The invention provides methods for using expression levels of Fas to select individuals or subpopulation of individuals who can benefit from an anti-cancer therapy and for assessing whether an individual suspected of having or developing cancerous tumors will beneficially respond to an anticancer therapy. The invention additionally provides methods of treatment for individuals selected as likely to benefit from anti-cancer therapy based on Fas expression levels. | 2014-10-02 |
20140294755 | Materials and Methods Relating to Stem Cell Mobilization by Multi-Pegylated Granulocyte Colony Stimulating Factor - The present invention relates to the use of multi-PEGylated granulocyte colony stimulating factor (G-CSF) preparations to mobilize hematopoietic stem cells. | 2014-10-02 |
20140294756 | Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF - The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition. | 2014-10-02 |
20140294757 | STABILISATION OF POLYPEPTIDES - A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide. | 2014-10-02 |
20140294758 | LIGHT CHAIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE THEREOF - Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active. | 2014-10-02 |
20140294759 | TARGETING REGULATORY T CELLS WITH HETERODIMERIC PROTEINS - The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells. | 2014-10-02 |
20140294760 | NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON - The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman. | 2014-10-02 |
20140294761 | TREATMENTS FOR MIGRAINE AND RELATED DISORDERS - Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies for migraine events and related headaches. | 2014-10-02 |
20140294762 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 2014-10-02 |
20140294763 | PEPTIDOMIMETIC PROTEASE INHIBITORS - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 2014-10-02 |
20140294764 | COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO - This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes. | 2014-10-02 |
20140294765 | LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER - This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer. | 2014-10-02 |
20140294766 | Anti-Infective Agents and Uses Thereof - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 2014-10-02 |
20140294767 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR - A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G | 2014-10-02 |
20140294768 | RESPONSIVENESS TO ANGIOGENESIS INHIBITORS - The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene. | 2014-10-02 |
20140294769 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV - Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2′,4′-fluoro nucleosides according to Formula 1001: | 2014-10-02 |
20140294770 | COMPOSITIONS AND METHODS FOR SPINAL DISC REPAIR AND OTHER SURGICAL AND NON-SURGICAL INDICATIONS - The present invention features, inter alia, biocompatible compositions that include a poloxamer and one or more additives such as hyaluronic acid, gelatin, fibronectin, or a peptide fragment of fibronectin. The compositions are useful in tissue repair or remodeling, including repair of an injured spinal disc, in drug delivery, in cell culture, and in inhibiting the formation of adhesions. | 2014-10-02 |
20140294771 | Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof - The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease. | 2014-10-02 |
20140294772 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS - Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles. | 2014-10-02 |
20140294773 | MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOF - A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression. A pair of ribonucleotides fused to Fold dimers may be used to generate double-strand breakages in the DNA to facilitate these applications in a sequence-specific manner. | 2014-10-02 |
20140294774 | METHOD FOR PREVENTING AND/OR TREATING INSULIN RESISTANCE - Described is the use of | 2014-10-02 |
20140294775 | METHODS FOR TREATING OBESITY AND/OR METABOLIC SYNDROME - The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1 | 2014-10-02 |
20140294776 | Isolated populations of female germline stem cells and cell preparations and compositions thereof - The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. | 2014-10-02 |
20140294777 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 2014-10-02 |
20140294778 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS - Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells. | 2014-10-02 |
20140294779 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 2014-10-02 |
20140294780 | COMPOSITIONS AND METHODS FOR INDUCTION AND MODULATION OF ANGIOGENESIS AND METHODS AND ASSAYS FOR IDENTIFYING ANGIOGENESIS MODULATORS - The present disclosure provides methods and compositions, including a placental extract, for inducing and/or modulating angiogenesis; methods of identifying modulators of angiogenesis, and assays for identifying modulators of angiogenesis. The present disclosure also provides methods of making a composition, including a placental extract that can induce and/or modulate angiogenesis. | 2014-10-02 |
20140294781 | Method to formulate T-cells - A method for formulating T-cells for use as a medicant comprises suspending T-cells with cross-linked surface moieties in a media suitable for infusion. The cross-linked T-cells are packaged in a container suitable for administration to a patient. | 2014-10-02 |
20140294782 | Reprogramming of Cellular Adhesion - Disclosed are membrane-anchored polynucleotides, and compositions comprising the membrane-anchored polynucleotides. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds and compositions in research and therapeutic applications. | 2014-10-02 |
20140294783 | IMPLANTABLE SCAFFOLDS AND METHODS OF USE - Inventive concepts relate general to the field of implantable three-dimensional scaffolds. More particularly, methods of preparing and using implantable nanofibrous tissue scaffolds are described. Inventive scaffolds can be used for treatment of defects in a living organism, such as hard or soft tissue defects including bone. | 2014-10-02 |
20140294784 | Cell-Based Anti-Cancer Compositions With Reduced Toxicity And Methods Of Making And Using The Same - Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules. | 2014-10-02 |
20140294785 | DOSAGE COMPENSATING TRANSGENES AND CELLS - Methods and compositions for reducing expression of genes on Chromosome 21 (“Chr 21”) by targeting an XIST transgene to the Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene or a Regulator of calcineurin 1 (RCAN1) gene, and cells and transgenic animals comprising an XIST transgene inserted into a DYRK1A or RCAN1 allele, e.g., cells and animals trisomic for human Chr 21 and mouse Chr 16. | 2014-10-02 |
20140294786 | Alimentary Protein-Based Scaffolds (APS) for Wound Healing, Regenerative Medicine and Drug Discovery - The invention provides engineered biomaterials derived from plant products. The engineered biomaterials are useful for biomedical applications. The engineered biomaterials are able to support the growth of animal calls. | 2014-10-02 |
20140294787 | EXTENSIONAL VISCOSITY TO PROMOTE SAFE SWALLOWING OF FOOD BOLUSES - Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of at least 6. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided. | 2014-10-02 |
20140294788 | METHODS FOR ENHANCING MUSCLE PROTEIN SYNTHESIS FOLLOWING CONCURRENT TRAINING - The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training. Programs for enhancing muscle adaptation resulting from concurrent training are also provided. The programs include providing a composition comprising from about 15 to about 35 g protein; and providing guidelines for consumption including a recommendation of the amount of the composition to consume immediately following concurrent training. | 2014-10-02 |
20140294789 | GALACTOOLIGOSACCHARIDES FOR PREVENTING INJURY AND/OR PROMOTING HEALING OF THE GASTROINTESTINAL TRACT - Disclosed are nutritional compositions including galactooligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, children, and adults for preventing injury and/or improving the healing of the gastrointestinal tract. Additional suitable methods of using the nutritional compositions including the galactooligosaccharides are also disclosed. | 2014-10-02 |
20140294791 | Lactobacillus paracasei subsp. paracasei, as an agent for inhibiting listeria monocytogenes in vivo infection - The present invention relates to the use of the probiotic strain of | 2014-10-02 |
20140294792 | T-REG Cell Expansion - This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases. | 2014-10-02 |
20140294793 | GPR15-MEDIATED HOMING AND USES THEREOF - The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes. | 2014-10-02 |
20140294794 | METHODS FOR TREATING BLEEDING DISORDERS USING A PLATELET SUBPOPULATION - The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor VII (rFVIIa), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rFVIIa. | 2014-10-02 |
20140294795 | Nutritional Composition - The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals. | 2014-10-02 |
20140294796 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME - The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant. | 2014-10-02 |
20140294797 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. | 2014-10-02 |
20140294798 | RbAp48 TRANSGENIC MICE FOR DRUG DISCOVERY IN AGE-RELATED MEMORY DECLINE - Described is a transgenic mouse with two transgenes, each of which transgene comprises a DNA sequence encoding a dominant negative form of RbAp48 protein, wherein the expression of the dominant negative form of RbAp48 is spatially restricted to the forebrain by a CaM Kinase IIa promoter and wherein the expression of the dominant negative form of RbAp48 is controlled by tetracycline-controlled transcriptional activation. Also provided are methods for evaluating in the transgenic mouse the potential therapeutic effect of an agent for slowing, inhibiting or preventing age-related memory decline in a mammalian subject. | 2014-10-02 |
20140294799 | USE OF COMPOSITIONS HAVING A LOW POLYAMINE CONTENT IN THE PREVENTION OR TREATMENT OF ADVERSE EFFECTS LINKED TO CANCER TREATMENT - The composition includes, per gram of composition, less than 600, in particular less than 400 picomoles of biologically active polyamines, for use in the prevention or treatment of radiotherapy-induced pathologies of the skin or mucous membranes in a patient, in particular a human or an animal. | 2014-10-02 |
20140294800 | METHOD OF CHARACTERIZING LYSOSOMAL ENZYMES - The present invention provides, among other things, methods for the characterization of recombinant Heparan N-Sulfatase (HNS) during manufacture. The present invention uses capillary zone electrophoresis to determine the charge profile, isoform distribution, and/or glycan profile of recombinant HNS; and represents a quality feature for the batch consistency, storage stability, biological half-life, pharmacokinetic, pharmacodynamic and biological activity of the enzyme. In particular, such characterization methods may be beneficial to optimize conditions and ensure consistency for the manufacture of HNS for the treatment of a patient diagnosed with Sanfilippo syndrome using enzyme replacement therapy. | 2014-10-02 |
20140294801 | SEQUENCE-SPECIFIC MRNA INTERFERASE AND USES THEREOF - The present invention provides an improved and specific mRNA interferase and related methods of protein-based mRNA interference. | 2014-10-02 |
20140294802 | METHODS AND COMPOSITIONS TO REDUCE SERUM LEVELS OF TRIACYLGLYCERIDES IN HUMAN BEINGS USING A FUNGAL LIPASE - The invention relates to methods and compositions for reducing serum levels of triacylglycerides in human subjects. In particular, the invention relates to the oral administration of an effective amount of a fungal lipase formulation, to a human subject having borderline-high or high serum levels of triacylglycerides, for a time period sufficient to reduce serum triacylglyceride levels. | 2014-10-02 |
20140294803 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 2014-10-02 |
20140294804 | METHODS OF TREATING PAIN - The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity. | 2014-10-02 |
20140294805 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT - The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: | 2014-10-02 |
20140294806 | Methods and compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate - This invention provides methods and compositions useful for treating early and late stage metastatic cancer to prevent or treat acquired resistance due to gene amplification or mutation in response to chemotherapeutic and/or targeted drugs. In particular, the methods and compositions include carboxiamidotriazole orotate (CTO) alone or in combination with specific regimens of chemotherapeutic and/or targeted drugs designed to overcome the genomic resistance raised to prior therapy. | 2014-10-02 |
20140294807 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody. | 2014-10-02 |
20140294808 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS - Methods of treating cancer with a compound of formulae (I) or (Ia) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (Ia). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (Ia); a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. | 2014-10-02 |
20140294809 | Anti-Alpha(v)Beta(6) Antibodies and Uses Thereof - The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize α | 2014-10-02 |
20140294810 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF - Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided. | 2014-10-02 |
20140294811 | METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY - The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene. | 2014-10-02 |
20140294812 | FC VARIANTS THAT IMPROVE FCRN BINDING AND/OR INCREASE ANTIBODY HALF-LIFE - The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life. | 2014-10-02 |
20140294813 | TNF Binding Proteins - Provided are TNF binding proteins and methods of treatment using the same. Also provided are nucleic acids encoding the binding proteins and recombinant expression vectors and host cells for making such binding proteins. | 2014-10-02 |
20140294814 | HUMANIZED AND AFFINITY-MATURED ANTI-C-MET ANTIBODY AND USES THEREOF - Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody. | 2014-10-02 |
20140294815 | CANINISED TUMOUR NECROSIS FACTOR ANTIBODIES AND METHODS OF USING THE SAME - Caninised and chimeric antibodies and antigen binding fragments thereof which bind specifically to canine tumour necrosis factor and inhibit the ability of canine TNF to bind to the TNFR1 receptor are provided. The invention further extends to nucleic acids encoding same and to methods of treating chronic inflammatory disease such as arthritis in a canine using said antibodies and/or nucleic acids. | 2014-10-02 |
20140294816 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2014-10-02 |
20140294817 | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME - Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein. | 2014-10-02 |
20140294818 | PGAM1 INHIBITORS AND METHODS RELATED THERETO - In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof. | 2014-10-02 |
20140294819 | CANINE/FELINE CD20 BINDING EPITOPE AND COMPOSITIONS FOR BINDING THERETO - The present invention provides acyclic polypeptide fragment of CD20 comprising (i) a contiguous amino acid sequence consisting of amino acid residues SEKNS (SEQ ID NO:67); (ii) a first cysteine residue which is present at a region N-terminal to the contiguous amino acid sequence and (iii) a second cysteine residue which is present at a region C-terminal to the contiguous amino acid sequence, wherein the cyclic polypeptide is oxidised by the presence of a disulphide bond formed between the first and second cysteine residues. Also described is the use of the cyclic peptide fragment to generate antibodies which bind specifically to CD20. Antibodies which bind specifically to the cyclic peptide fragment for use in treatment of B-cell mediated conditions in felines and canines are also described. | 2014-10-02 |
20140294820 | FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION FOR THE TREATMENT OF DISEASE - Methods of inhibiting fibroblast growth factor mediated activation of fibroblast growth factor receptors for the treatment of chronic kidney disease, diabetes, and cardiac diseases are enclosed. Pharmaceutical compositions for the treatment of such diseases using the methods are also disclosed as are methods of determining whether a subject would benefit from the methods of treatment and pharmaceutical compositions. | 2014-10-02 |
20140294821 | FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF - The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells | 2014-10-02 |
20140294822 | METHODS AND COMPOSITIONS FOR INCREASING ARYLSULFATASE A ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 2014-10-02 |
20140294823 | HETERODIMERIC PROTEINS - The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings. | 2014-10-02 |
20140294824 | ANTIBODIES THAT BIND TO OX40 AND THEIR USES - The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6. | 2014-10-02 |
20140294825 | HYBRID CONSTANT REGIONS - The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and Cμ3 and Cμ4 regions of a Cμ constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a Cμ constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89. | 2014-10-02 |
20140294826 | Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure - Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a ricin toxin, a Shiga toxin, or an anthrax toxin. | 2014-10-02 |
20140294827 | Fully Human Antibodies that Bind to VEGFR2 - There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers. | 2014-10-02 |
20140294828 | ALPHABODIES SPECIFICALLY BINDING TO VIRAL PROTEINS AND METHODS FOR PRODUCING THE SAME - The invention provides methods for the production of single-chain Alphabody polypeptides having detectable binding affinity for, or detectable in vitro activity on, a viral protein of interest, which comprising the step of producing a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein said variegated amino acid residue positions are located at specific positions in one or more of the alpha-helices of the Alphabody or the linker fragment connecting two consecutive alpha-helices of the Alphabody polypeptides. The invention further provides Alphabodies obtainable by the methods of the invention and uses thereof. | 2014-10-02 |